<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="112826">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02143466</url>
  </required_header>
  <id_info>
    <org_study_id>D5160C00006</org_study_id>
    <nct_id>NCT02143466</nct_id>
  </id_info>
  <brief_title>AZD9291 in Combination With Ascending Doses of Novel Therapeutics</brief_title>
  <official_title>A Multi-arm, Phase Ib, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of AZD9291 in Combination With Ascending Doses of Novel Therapeutics in Patients With EGFRm+ Advanced NSCLC Who Have Progressed Following Therapy With an EGFR TKI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety, tolerability and preliminary
      anti-tumour activity of AZD9291 when given together with one of either MEDI4736, AZD6094 OR
      selumetinib in patients with EGFR mutation positive advanced lung cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase Ib, Open-Label, Multiarm, Multicentre Study to Assess the Safety, Tolerability,
      Pharmacokinetics and Preliminary Anti-tumour Activity of AZD9291 in Combination with
      Ascending Doses of Novel Therapeutics in Patients with EGFRm+ Advanced NSCLC who have
      progressed following therapy with an EGFR TKI
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Anticipated">August 2015</completion_date>
  <primary_completion_date type="Anticipated">August 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Safety and tolerability of AZD9291 when given in combination with MEDI4736, AZD6094 or selumetinib</measure>
    <time_frame>Adverse events will be collected from baseline until 28 days after the last dose in the AZD6094 or selumetinib arms and until 90 days after the last dose in the MEDI4736 arm, expected average 7.5 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To investigate the safety and tolerability of AZD9291 when given orally to patients with EGFRm+ NSCLC in combination with MEDI4736, AZD6094 or selumetinib who have progressed following prior therapy with an EGFR TKI agent, and define the combination dose(s) for further clinical evaluation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax after single dosing</measure>
    <time_frame>Blood samples will be collected from each subject at pre-specified times on cycle 1 day 1 up to 24 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>To characterise the pharmacokinetics of AZD9291, AZD6094, seleumetinib and metabolites after single dosing and at steady state after multiple dosing when given orally to patients with EGFRm+ NSCLC in combination with AZD9291, AZD6094 or selumetinib. To characterise the PK, immunogenicity and pharmacodynamics of MEDI4736 after single dosing and at steady state after multiple dosing when given intravenously to patients with EGFRm+ NSCLC in combination with AZD9291.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax after single dosing</measure>
    <time_frame>Blood samples will be collected from each subject at pre-specified on cycle 1 day 1 up to 24 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>To characterise the pharmacokinetics of AZD9291, AZD6094, seleumetinib and metabolites after single dosing and at steady state after multiple dosing when given orally to patients with EGFRm+ NSCLC in combination with AZD9291, AZD6094 or selumetinib. To characterise the PK, immunogenicity and pharmacodynamics of MEDI4736 after single dosing and at steady state after multiple dosing when given intravenously to patients with EGFRm+ NSCLC in combination with AZD9291.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC after single dosing</measure>
    <time_frame>Blood samples will be collected from each subject at pre-specified times on cycle 1 day 1 up to 24 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>To characterise the pharmacokinetics of AZD9291, AZD6094, seleumetinib and metabolites after single dosing and at steady state after multiple dosing when given orally to patients with EGFRm+ NSCLC in combination with AZD9291, AZD6094 or selumetinib. To characterise the PK, immunogenicity and pharmacodynamics of MEDI4736 after single dosing and at steady state after multiple dosing when given intravenously to patients with EGFRm+ NSCLC in combination with AZD9291.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-t after single dosing</measure>
    <time_frame>Blood samples will be collected from each subject at pre-specified on cycle 1 day 1 up to 24 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>To characterise the pharmacokinetics of AZD9291, AZD6094, seleumetinib and metabolites after single dosing and at steady state after multiple dosing when given orally to patients with EGFRm+ NSCLC in combination with AZD9291, AZD6094 or selumetinib. To characterise the PK, immunogenicity and pharmacodynamics of MEDI4736 after single dosing and at steady state after multiple dosing when given intravenously to patients with EGFRm+ NSCLC in combination with AZD9291.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-24 after single dosing</measure>
    <time_frame>Blood samples will be collected from each subject at pre-specified times on cycle 1 day 1 up to 24 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>To characterise the pharmacokinetics of AZD9291, AZD6094, seleumetinib and metabolites after single dosing and at steady state after multiple dosing when given orally to patients with EGFRm+ NSCLC in combination with AZD9291, AZD6094 or selumetinib. To characterise the PK, immunogenicity and pharmacodynamics of MEDI4736 after single dosing and at steady state after multiple dosing when given intravenously to patients with EGFRm+ NSCLC in combination with AZD9291.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-72 after single dosing</measure>
    <time_frame>Blood samples will be collected from each subject at pre-specified times on cycle 1 day 1 up to 24 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>To characterise the pharmacokinetics of AZD9291, AZD6094, seleumetinib and metabolites after single dosing and at steady state after multiple dosing when given orally to patients with EGFRm+ NSCLC in combination with AZD9291, AZD6094 or selumetinib. To characterise the PK, immunogenicity and pharmacodynamics of MEDI4736 after single dosing and at steady state after multiple dosing when given intravenously to patients with EGFRm+ NSCLC in combination with AZD9291.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half life after single dosing</measure>
    <time_frame>Blood samples will be collected from each subject at pre-specified times on cycle 1 day 1 up to 24 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>To characterise the pharmacokinetics of AZD9291, AZD6094, seleumetinib and metabolites after single dosing and at steady state after multiple dosing when given orally to patients with EGFRm+ NSCLC in combination with AZD9291, AZD6094 or selumetinib. To characterise the PK, immunogenicity and pharmacodynamics of MEDI4736 after single dosing and at steady state after multiple dosing when given intravenously to patients with EGFRm+ NSCLC in combination with AZD9291.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL after single dosing</measure>
    <time_frame>Blood samples will be collected from each subject at pre-specified times on cycle 1 day 1 up to 24 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>To characterise the pharmacokinetics of AZD9291, AZD6094, seleumetinib and metabolites after single dosing and at steady state after multiple dosing when given orally to patients with EGFRm+ NSCLC in combination with AZD9291, AZD6094 or selumetinib. To characterise the PK, immunogenicity and pharmacodynamics of MEDI4736 after single dosing and at steady state after multiple dosing when given intravenously to patients with EGFRm+ NSCLC in combination with AZD9291</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/f after single dosing</measure>
    <time_frame>Blood samples will be collected from each subject at pre-specified times on cycle 1 day 1 up to 24 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>To characterise the pharmacokinetics of AZD9291, AZD6094, seleumetinib and metabolites after single dosing and at steady state after multiple dosing when given orally to patients with EGFRm+ NSCLC in combination with AZD9291, AZD6094 or selumetinib. To characterise the PK, immunogenicity and pharmacodynamics of MEDI4736 after single dosing and at steady state after multiple dosing when given intravenously to patients with EGFRm+ NSCLC in combination with AZD9291</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution after single dosing</measure>
    <time_frame>Blood samples will be collected from each subject at pre-specified times on cycle 1 day 1 up to 24 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>To characterise the pharmacokinetics of AZD9291, AZD6094, seleumetinib and metabolites after single dosing and at steady state after multiple dosing when given orally to patients with EGFRm+ NSCLC in combination with AZD9291, AZD6094 or selumetinib. To characterise the PK, immunogenicity and pharmacodynamics of MEDI4736 after single dosing and at steady state after multiple dosing when given intravenously to patients with EGFRm+ NSCLC in combination with AZD9291.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cssmax after multiple dosing</measure>
    <time_frame>Blood samples will be collected from each subject at pre-specified times on cycle 2 day 1 up to 24 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>To characterise the pharmacokinetics of AZD9291, AZD6094, seleumetinib and metabolites after single dosing and at steady state after multiple dosing when given orally to patients with EGFRm+ NSCLC in combination with AZD9291, AZD6094 or selumetinib. To characterise the PK, immunogenicity and pharmacodynamics of MEDI4736 after single dosing and at steady state after multiple dosing when given intravenously to patients with EGFRm+ NSCLC in combination with AZD9291.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tssmax after multiple dosing</measure>
    <time_frame>Blood samples will be collected from each subject at pre-specified times on cycle 2 day 1 up to 24 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>To characterise the pharmacokinetics of AZD9291, AZD6094, seleumetinib and metabolites after single dosing and at steady state after multiple dosing when given orally to patients with EGFRm+ NSCLC in combination with AZD9291, AZD6094 or selumetinib. To characterise the PK, immunogenicity and pharmacodynamics of MEDI4736 after single dosing and at steady state after multiple dosing when given intravenously to patients with EGFRm+ NSCLC in combination with AZD9291.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cssmin after multiple dosing</measure>
    <time_frame>Blood samples will be collected from each subject at pre-specified times for the duration of treatment, expected to be 7.5 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To characterise the pharmacokinetics of AZD9291, AZD6094, seleumetinib and metabolites after single dosing and at steady state after multiple dosing when given orally to patients with EGFRm+ NSCLC in combination with AZD9291, AZD6094 or selumetinib. To characterise the PK, immunogenicity and pharmacodynamics of MEDI4736 after single dosing and at steady state after multiple dosing when given intravenously to patients with EGFRm+ NSCLC in combination with AZD9291.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCss after multiple dosing</measure>
    <time_frame>Blood samples will be collected from each subject at pre-specified times on cycle 2 day 1 up to 24 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>To characterise the pharmacokinetics of AZD9291, AZD6094, seleumetinib and metabolites after single dosing and at steady state after multiple dosing when given orally to patients with EGFRm+ NSCLC in combination with AZD9291, AZD6094 or selumetinib. To characterise the PK, immunogenicity and pharmacodynamics of MEDI4736 after single dosing and at steady state after multiple dosing when given intravenously to patients with EGFRm+ NSCLC in combination with AZD9291.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CLss/f after multiple dosing</measure>
    <time_frame>Blood samples will be collected from each subject at pre-specified times on cycle 2 day 1 up to 24 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>To characterise the pharmacokinetics of AZD9291, AZD6094, seleumetinib and metabolites after single dosing and at steady state after multiple dosing when given orally to patients with EGFRm+ NSCLC in combination with AZD9291, AZD6094 or selumetinib. To characterise the PK, immunogenicity and pharmacodynamics of MEDI4736 after single dosing and at steady state after multiple dosing when given intravenously to patients with EGFRm+ NSCLC in combination with AZD9291.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rac after multiple dosing</measure>
    <time_frame>Blood samples will be collected from each subject at pre-specified times on cycle 1 day 1 and cycle 2 day 1</time_frame>
    <safety_issue>No</safety_issue>
    <description>To characterise the pharmacokinetics of AZD9291, AZD6094, seleumetinib and metabolites after single dosing and at steady state after multiple dosing when given orally to patients with EGFRm+ NSCLC in combination with AZD9291, AZD6094 or selumetinib. To characterise the PK, immunogenicity and pharmacodynamics of MEDI4736 after single dosing and at steady state after multiple dosing when given intravenously to patients with EGFRm+ NSCLC in combination with AZD9291.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time dependency of PK after multiple dosing</measure>
    <time_frame>Blood samples will be collected from each subject at pre-specified times on cycle 1 day 1 and cycle 2 day 1</time_frame>
    <safety_issue>No</safety_issue>
    <description>To characterise the pharmacokinetics of AZD9291, AZD6094, seleumetinib and metabolites after single dosing and at steady state after multiple dosing when given orally to patients with EGFRm+ NSCLC in combination with AZD9291, AZD6094 or selumetinib. To characterise the PK, immunogenicity and pharmacodynamics of MEDI4736 after single dosing and at steady state after multiple dosing when given intravenously to patients with EGFRm+ NSCLC in combination with AZD9291.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best objective response</measure>
    <time_frame>At baseline and every 6 weeks until disease progression or withdrawal from study, expected average 7.5 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To obtain a preliminary assessment of the anti-tumour activity of the combination of AZD9291 and MEDI4736, AZD6094 or selumetinib by evaluation of tumour response (objective response rate, duration of response, change in tumour size) and progression free survival using RECIST version 1.1 (modified for MEDI4736 cohorts)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>At baseline and every 6 weeks until disease progression or withdrawal from study, expected average 7.5 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To obtain a preliminary assessment of the anti-tumour activity of the combination of AZD9291 and MEDI4736, AZD6094 or selumetinib by evaluation of tumour response (objective response rate, duration of response, change in tumour size) and progression free survival using RECIST version 1.1 (modified for MEDI4736 cohorts)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>At baseline and every 6 weeks until disease progression or withdrawal from study, expected average 7.5 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To obtain a preliminary assessment of the anti-tumour activity of the combination of AZD9291 and MEDI4736, AZD6094 or selumetinib by evaluation of tumour response (objective response rate, duration of response, change in tumour size) and progression free survival using RECIST version 1.1 (modified for MEDI4736 cohorts)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>At baseline and every 6 weeks until disease progression or withdrawal from study, expected average 7.5 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To obtain a preliminary assessment of the anti-tumour activity of the combination of AZD9291 and MEDI4736, AZD6094 or selumetinib by evaluation of tumour response (objective response rate, duration of response, change in tumour size) and progression free survival using RECIST version 1.1 (modified for MEDI4736 cohorts)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change in tumour size</measure>
    <time_frame>At baseline and every 6 weeks until disease progression or withdrawal from study, expected average 7.5 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To obtain a preliminary assessment of the anti-tumour activity of the combination of AZD9291 and MEDI4736, AZD6094 or selumetinib by evaluation of tumour response (objective response rate, duration of response, change in tumour size) and progression free survival using RECIST version 1.1 (modified for MEDI4736 cohorts)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>At baseline and every 6 weeks until disease progression or withdrawal from study, expected average 7.5 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To obtain a preliminary assessment of the anti-tumour activity of the combination of AZD9291 and MEDI4736, AZD6094 or selumetinib by evaluation of tumour response (objective response rate, duration of response, change in tumour size) and progression free survival using RECIST version 1.1 (modified for MEDI4736 cohorts)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Advanced Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>MEDI4736</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD9291 in combination with MEDI4736</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AZD6094</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD9291 in combination with AZD6094</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Selumetinib Continuous</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD9291 in combination with selumetinib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Selumetinib Intermittent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD9291 in combination with selumetinib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD9291 in combination with MEDI4736</intervention_name>
    <description>AZD9291 and MEDI4736 will be administered and if initial dosing is tolerated then subsequent cohorts will test increasing doses of AZD9291 and/or MEDI4736, until a recommended dose for further clinical evaluation is defined.</description>
    <arm_group_label>MEDI4736</arm_group_label>
    <other_name>AZD9291 &amp; MEDI4736</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD9291 in combination with AZD6094</intervention_name>
    <description>AZD9291 and AZD6094 will be administered in combination. If tolerated, subsequent cohorts will test increasing doses of AZD9291 and/or AZD6094, until a recommended dose for further clinical evaluation is defined.</description>
    <arm_group_label>AZD6094</arm_group_label>
    <other_name>AZD9291 &amp; Volitinib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD9291 in combinatin with selumetinib</intervention_name>
    <description>AZD9291 and selumetinib will be administered in combination. If tolerated, subsequent cohorts will test increasing doses of AZD9291 and/or selumetinib, until a recommended dose for further clinical evaluation is defined.</description>
    <arm_group_label>Selumetinib Continuous</arm_group_label>
    <other_name>AZD9291 &amp; AZD6244</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD9291 in combination with selumetinib</intervention_name>
    <description>AZD9291 will be administered with intermittent doses of selumetinib. If tolerated, subsequent cohorts will test increasing doses of AZD9291 and/or selumetinib, until a recommended dose for further clinical evaluation is defined.</description>
    <arm_group_label>Selumetinib Intermittent</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of signed and dated, written informed consent prior to any study specific
             procedures, sampling and analyses Aged at least 18 years. Patients from Japan aged at
             least 20 years. Histological or cytological confirmation diagnosis of EGFRm+ Non
             Small Cell Lung Cancer (NSCLC).

          -  Disease progression on previous treatment with a single-agent EGFR TKI (e.g.
             gefitinib or erlotinib).

          -  Confirmation from a previous archival sample that the tumour harbours an EGFR
             mutation known to be associated with EGFR TKI sensitivity (including exon 19 deletion
             and L858R).

          -  At least one lesion that can be used as a measurable lesion for the purposes of
             RECIST assessments WHO performance status 0-1 with no deterioration over the previous
             2 weeks and minimum life expectancy of 12 weeks Females should be using adequate
             contraceptive measures, should not be breast feeding and must have a negative
             pregnancy test prior to start of dosing or evidence of non-child bearing potential.

          -  Male patients should be willing to use barrier contraception.

        Exclusion Criteria:

          -  Treatment with an EGFR TKI within approximately 5x half-life of the first dose of
             study treatment.

          -  Any cytotoxic chemotherapy, investigational agents or other anticancer drugs from a
             previous treatment regimen or clinical study within 14 days of the first dose of
             study treatment.

          -  AZD9291 in the present study (ie, dosing previously initiated in this study). Prior
             or current exposure to or treatment with any anti-PD-L1 or anti-PD-1 antibodies,
             AZD6094 or another cMet inhibitor or selumetinib or any MEK, RAS or RAF inhibitor if
             allocated to MEDI4736, AZD6094 or selumetinib respectively.

          -  Current leptomeningeal metastases or spinal cord compression. Brain metastases are
             only permitted if treated, asymptomatic, and stable (not requiring steroids for at
             least 4 weeks prior to start of study treatment).

          -  Cardiac problems including but not limited to QT interval (QTc) &gt; 470 msec,
             abnormalities in rhythm, abnormalities in conduction or morphology of resting ECG,
             uncontrolled hypertension, uncontrolled hypotension, left ventricular ejection
             fraction &lt;55%, symptomatic heart failure, ventricular rate &gt;100 bpm, cardiomyopathy,
             uncontrolled angina, stroke, acute coronary syndrome Ophthalmological conditions
             including intra-ocular pressure &gt;21 mmHg, uncontrolled glaucoma (irrespective of
             intra-ocular pressure), central serous retinopathy or retinal vein occlusion Any
             evidence of severe or uncontrolled systemic diseases, including uncontrolled
             hypertension, active bleeding diatheses, or active infection.

          -  Inadequate bone marrow reserve or organ function Inability to swallow the formulated
             product or previous significant bowel resection that would preclude adequate
             absorption Past medical history of interstitial lung disease, drug-induced
             interstitial lung disease, radiation pneumonitis which required steroid treatment, or
             any evidence of clinically active interstitial lung disease.

          -  Additional Exclusion criteria for MEDI4736 arm Active or prior documented autoimmune
             or inflammatory disease (including inflammatory bowel disease, diverticulitis with
             the exception of diverticulosis, celiac disease, irritable bowel disease, Wegner
             syndrome, Hashimoto syndrome) within the past 3 years.

          -  History of organ transplant that requires use of immunosuppressive medications
             including, but not limited to systemic corticosteroids at doses beyond 10 mg/day of
             prednisone or equivalent, methotrexate, azathioprine, and tumour necrosis factor
             alpha (TNF-α) blockers.

          -  History of sarcoidosis syndrome Known history of tuberculosis Receipt of live,
             attenuated vaccine within 30 days prior to the first dose of MEDI4736 Current or
             prior use of immunosuppressive medication within 28 days before the first dose of
             MEDI4736 Additional exclusion criteria for AZD6094 arm Patients currently receiving
             (or unable to stop use at least 2 weeks) prior to receiving the first dose of
             AZD6094, medications known to be strong inhibitors of CYP1A2
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Serban Ghiorghiu</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>AstraZeneca Clinical Study Information</last_name>
    <email>ClinicalTrialTransparency@astrazeneca.com</email>
  </overall_contact>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 19, 2014</lastchanged_date>
  <firstreceived_date>May 9, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase I</keyword>
  <keyword>Safety</keyword>
  <keyword>Tolerability</keyword>
  <keyword>Anti-tumour</keyword>
  <keyword>AZD9291</keyword>
  <keyword>MEDI4736</keyword>
  <keyword>AZD6094</keyword>
  <keyword>Selumetinib</keyword>
  <keyword>Ascending Doses</keyword>
  <keyword>EGFR</keyword>
  <keyword>Advanced Non-Small Cell Lung Cancer</keyword>
  <keyword>Tyrosine Kinase Inhibitors</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
